Tuilleadh eolais ― Gaeilge

Is é Squamous cell carcinoma (SCC) an dara ailse craicinn is coitianta sna Stáit Aontaithe, tar éis basal cell carcinoma. Tosaíonn sé de ghnáth ó lesa réamhailse ar a dtugtar actinic keratosis, agus féadann sé scaipeadh go codanna eile den chorp. Is é an phríomhchúis ná nochtadh do ultraviolet (UV) ón ngrian, a charnann le himeacht ama. De ghnáth baineann cóireáil le baint máinliachta, go háirithe le haghaidh SCC ar an ceann agus ar an muineál. Is rogha í teiripe radaíochta d’othair níos sine nó dóibh siúd nach féidir leo máinliacht a fháil. Méadaíonn imdhíonú (immunosuppression) an baol SCC. Cé gur annamh, is féidir le SCC scaipeadh, go háirithe i n-othair a bhfuil córais imdhíonachta lagaithe acu. Tá seiceálacha rialta agus cosaint gréine tábhachtach dóibh siúd a bhfuil SCC acu.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.

Is é Cutaneous squamous cell carcinoma (CSCC) an dara cancair craicinn is coitianta i measc an phobail, agus tá a líon ag dul suas. Cé go léiríonn CSCC iompair cliniciúil benign (benign) de ghnáth, féadann sé bheith ionsaitheach go háitiúil agus scaipeadh go codanna eile den chorp. D’ aithin eolaithe conairí sonracha a bhfuil baint acu le forbairt CSCC, as a dtiocfaidh cóireálacha nua. Bhí an líon ard sócháin agus an baol méadaithe i measc othar atá faoi imdhíonta mar chuid den chúis le forbairt imdhíonta (immunotherapy) do CSCC. Breathnaítear san athbhreithniú seo ar fhréamhacha géiniteacha CSCC agus ar na cóireálacha is déanaí a dhíríonn ar mhóilíní spriocdhírithe agus ar an gcóras imdhíonachta.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors